早产儿视网膜病变与脑白质成熟及早期发育结局的关系
本研究纳入84例早产儿,在足月等效年龄行弥散张量成像(DTI)生成26条脑白质通路概率图,比较有无视网膜病变(ROP)者的各向异性分数(FA)与平均弥散率(MD),并在矫正年龄18个月时用BSID-III评估发育结局。结果显示ROP或严重ROP与白质通路成熟及发育结局均无显著关联,接受与未接受贝伐珠单抗治疗的ROP患儿之间也无显著差异。
要点
- ROP或严重ROP与26条脑白质通路的FA和MD值无显著关联。
- ROP患儿是否接受贝伐珠单抗治疗,白质通路FA和MD无显著差异。
- 有无ROP或严重ROP的早产儿18个月BSID-III评分无显著差异。
核心结论
- ROP或严重ROP与早产儿脑白质通路成熟延迟无显著关联。
- 有无ROP或严重ROP的早产儿18个月发育结局相似。
- ROP患儿接受与未接受玻璃体腔贝伐珠单抗治疗的发育结局相似。
研究设计与样本
- 前瞻性队列研究,纳入84例早产儿,于足月等效年龄行DTI生成26条与运动、认知、视觉及边缘/语言功能相关的白质通路概率图。
- 比较有无ROP及有无严重ROP者的FA和MD值,并在矫正年龄18个月用BSID-III评估发育结局。
- 采用多元回归分析校正潜在混杂因素后确认发育结局、白质通路与ROP或严重ROP的关联。
主要发现
- 白质通路与ROP或严重ROP的关联不显著。
- ROP患儿接受与未接受贝伐珠单抗治疗者,白质通路FA和MD值无显著差异。
- 有无ROP或严重ROP的早产儿BSID-III评分无显著差异。
- 18个月BSID-III评分与多条白质通路的FA或MD值显著相关。
临床怎么用
- 对于早产儿ROP患儿,白质成熟和18个月发育结局与无ROP者相似,无需仅因ROP诊断而预期白质发育延迟。
- ROP患儿接受贝伐珠单抗治疗与否,白质通路和发育结局无显著差异,治疗决策可主要基于ROP本身指征。
- 18个月BSID-III评分与多条白质通路FA或MD值显著相关,提示DTI指标或可辅助评估发育风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate brain white matter pathways using magnetic resonance diffusion tensor imaging (DTI) and correlate the findings with developmental outcomes at 18 months of corrected age in preterm infants with and without retinopathy of prematurity (ROP). METHODS: In this prospective cohort study, probabilistic maps of the 26 white matter pathways associated with motor, cognitive, visual, and limbic/language functions were generated in 84 preterm infants using DTI obtained at term-equivalent age. The mean fractional anisotropy (FA) and mean diffusivity (MD) values were compared between those with and without ROP. Developmental outcomes were assessed using the third edition of Bayley Scales of Infant and Toddler Development (BSID-III) at 18 months of corrected age. Multiple regression analyses were performed to confirm the association among developmental outcomes, white matter pathways, and ROP or severe ROP after adjusting for potential confounders. RESULTS: The white matter pathways were insignificantly associated with ROP or severe ROP. There were no significant differences in the FA and MD values of the pathways between ROP infants treated with and without bevacizumab therapy. Furthermore, there were no significant differences in BSID-III scores between infants with and without ROP or severe ROP. The BSID-III scores at 18 months of age showed a significant association with FA or MD values in several pathways. CONCLUSIONS: ROP or severe ROP was insignificantly associated with maturation delay of the white matter pathways. Developmental outcomes were similar between preterm infants with and without ROP or severe ROP or between ROP infants with and without intravitreal bevacizumab therapy.
引用
- Ahn SJ, Lee JY, Lee JY, et al. Brain White Matter Maturation and Early Developmental Outcomes in Preterm Infants With Retinopathy of Prematurity. Invest Ophthalmol Vis Sci. 2021. PMID: 33523200. doi:10.1167/iovs.62.2.2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。